Hans Melander

Summary

Affiliation: Medical Products Agency
Country: Sweden

Publications

  1. ncbi request reprint [Treatment of depression in children and adolescents: SSRI can/should be used after individual assessment]
    Hans Melander
    Läkemedelsverket
    Lakartidningen 104:3798-800; discussion 3800. 2007
  2. doi request reprint A regulatory Apologia--a review of placebo-controlled studies in regulatory submissions of new-generation antidepressants
    Hans Melander
    Medical Products Agency, P O Box 26, SE 751 03 Uppsala, Sweden
    Eur Neuropsychopharmacol 18:623-7. 2008
  3. pmc Evidence b(i)ased medicine--selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications
    Hans Melander
    Medical Products Agency, Box 23, S 751 03 Uppsala, Sweden
    BMJ 326:1171-3. 2003
  4. ncbi request reprint [Selective reporting--greater problem than selective publishing?]
    Hans Melander
    Läkemedelsvärdering, Läkemedelsverket, Uppsala
    Lakartidningen 102:224-5. 2005
  5. ncbi request reprint [Uneven sex distribution in the cardiovascular trials--an exaggerated problem]
    Hans Melander
    Lakartidningen 103:1856-9. 2006
  6. ncbi request reprint The conscientious judgement of a DSMB--statistical stopping rules re-examined
    Karin Hedenmalm
    Clinical Trial Unit, Medical Products Agency, Box 26, 751 03, Uppsala, Sweden
    Eur J Clin Pharmacol 64:69-72. 2008

Detail Information

Publications6

  1. ncbi request reprint [Treatment of depression in children and adolescents: SSRI can/should be used after individual assessment]
    Hans Melander
    Läkemedelsverket
    Lakartidningen 104:3798-800; discussion 3800. 2007
  2. doi request reprint A regulatory Apologia--a review of placebo-controlled studies in regulatory submissions of new-generation antidepressants
    Hans Melander
    Medical Products Agency, P O Box 26, SE 751 03 Uppsala, Sweden
    Eur Neuropsychopharmacol 18:623-7. 2008
    ..Differences in the percentage of patients experiencing a clinically relevant response should also be demonstrated. In this respect, the approved SSRIs and SNRIs were found superior to placebo, independent of severity of depression...
  3. pmc Evidence b(i)ased medicine--selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications
    Hans Melander
    Medical Products Agency, Box 23, S 751 03 Uppsala, Sweden
    BMJ 326:1171-3. 2003
    ..To investigate the relative impact on publication bias caused by multiple publication, selective publication, and selective reporting in studies sponsored by pharmaceutical companies...
  4. ncbi request reprint [Selective reporting--greater problem than selective publishing?]
    Hans Melander
    Läkemedelsvärdering, Läkemedelsverket, Uppsala
    Lakartidningen 102:224-5. 2005
  5. ncbi request reprint [Uneven sex distribution in the cardiovascular trials--an exaggerated problem]
    Hans Melander
    Lakartidningen 103:1856-9. 2006
  6. ncbi request reprint The conscientious judgement of a DSMB--statistical stopping rules re-examined
    Karin Hedenmalm
    Clinical Trial Unit, Medical Products Agency, Box 26, 751 03, Uppsala, Sweden
    Eur J Clin Pharmacol 64:69-72. 2008
    ..A number of other studies in which complex decisions were made by DSMBs are also reviewed...